BRIGHT MINDS BIOSCIENCES INC. (DRUG)
$72.81-$1.72 (-2.31%) Today
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
No Form 4 activity for DRUG in the last 90 days.
2 Form 4 filings on record, the earliest from Oct 17, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Cormorant Asset Management, LP | Open-market purchase | Common Shares | 184,331 | $21.70 | $4.00M | |
| Cormorant Asset Management, LP | Open-market purchase | Common Shares | 238,097 | $4.53 | $1.08M | |
| Cormorant Asset Management, LP | Open-market purchase | Common Shares | 63,173 | $5.92 | $374K | |
| Cormorant Asset Management, LP | Open-market purchase | Common Shares | 33,343 | $6.42 | $214K | |
| Cormorant Asset Management, LP | Open-market purchase | Common Shares | 8,900 | $7.31 | $65K | |
| Cormorant Asset Management, LP | Open-market purchase | Common Shares | 2,600 | $8.80 | $23K | |
| Cormorant Asset Management, LP | Open-market purchase | Common Shares | 2,700 | $9.26 | $25K | |
| Cormorant Asset Management, LP | Open-market purchase | Common Shares | 19,169 | $11.72 | $225K | |
| Cormorant Asset Management, LP | Open-market purchase | Common Shares | 4,609 | $12.35 | $57K | |
| Cormorant Asset Management, LP | Open-market purchase | Common Shares | 39,743 | $23.22 | $923K | |
| Cormorant Asset Management, LP | Open-market purchase | Common Shares | 7,150 | $24.03 | $172K | |
| Cormorant Asset Management, LP | Open-market purchase | Common Shares | 3,107 | $25.22 | $78K |
BRIGHT MINDS BIOSCIENCES INC. (DRUG) has filed no insider reports in the last 90 days. The most recent on record is dated 2024-11-06. The full record for DRUG runs to 2 Form 4 filings, the earliest from 2024-10-17. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of DRUG were filed in the last 90 days. 12 purchases are on record for this company.
No insider sales of DRUG were filed in the last 90 days.
This page tracks DRUG Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add DRUG to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
$DSACDaedalus Special Acquisition Corp.
$DSCDSC Holdings Ltd.
$DSCRXDiamond Hill Securitized Credit Fund
$DSLDoubleLine Income Solutions Fund
$DSMBNY MELLON STRATEGIC MUNICIPAL BOND FUND, INC.
$DSNYDESTINY MEDIA TECHNOLOGIES INC
$DSUBLACKROCK DEBT STRATEGIES FUND, INC.
$DSXDIANA SHIPPING INC.
$DTDTDT House Ltd
$DTFDTF TAX-FREE INCOME 2028 TERM FUND INCEvery Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.